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Context: Primary pigmented nodular adrenocortical disease (PPNAD) can lead to steroid hormone
overproduction. Mutations in the cAMP protein kinase A regulatory subunit type 1A (PRKAR1A) are
causative of PPNAD. Steroidogenesis in PPNAD can be modified through a local glucocorticoid feed-
forward loop.
Objective: Investigation of regulation of steroidogenesis in a case of PPNAD with virilization.
Materials and methods: A 33-year-old woman presented with primary infertility due to hyperandrogen-
ism. Elevated levels of testosterone and subclinical ACTH-independent Cushing’s syndrome led to the
discovery of an adrenal tumor, which was diagnosed as PPNAD. In vivo evaluation of aberrantly
expressed hormone receptors showed no steroid response to known stimuli. Genetic analysis revealed a
PRKAR1A protein-truncating Q28X mutation. After adrenalectomy, steroid levels normalized. Tumor
cells were cultured and steroidogenic responses to ACTH and dexamethasone were measured and
compared with those in normal adrenal and adrenocortical carcinoma cells. Expression levels of
17b-hydroxysteroid dehydrogenase (17b-HSD) types 3 and 5 and steroid receptors were quantified
in PPNAD, normal adrenal, and adrenal adenoma tissues.
Results: Isolated PPNAD cells, analogous to normal adrenal cells, showed both increased steroidogenic
enzyme expression and steroid secretion in response to ACTH. Dexamethasone did not affect steroid
production in the investigated types of adrenal cells. 17b-HSD type 5 was expressed at a higher level in
the PPNAD-associated adenoma compared with control adrenal tissue.
Conclusion: PPNAD-associated adenomas can cause virilization and infertility by adrenal androgen
overproduction. This may be due to steroidogenic control mechanisms that differ from those described
for PPNAD without large adenomas.
European Journal of Endocrinology 168 67–74Introduction
Primary pigmented nodular adrenocortical disease
(PPNAD) constitutes a rare cause of adrenocortical
hyperplasia and ACTH-independent Cushing’s syn-
drome. PPNAD can occur sporadically or in conjunction
with other tumors in Carney complex (1). Known
genetic causes of PPNAD and Carney complex are
mutations in components of the cAMP protein kinase
A (PKA) pathway: PRKAR1A (2), PDE11A (3), and
PDE8B (4). The net effect of these mutations is
increased activity of the PKA catalytic subunits (2).
Aberrant cAMP–PKA signaling in the adrenal cortex
leads to hyperplasia, the formation of multiple pigmen-
ted nodules, and the sporadic formation of a largendocrinologytumor. The latter has been linked to mutations in
CTNNB1, which lead to constitutive activation and
nuclear translocation of its product b-catenin (5).
Other manifestations of Carney complex include
lentiginosis, myxomas, and pituitary, thyroid, and
testicular tumors (6).
PPNAD is the most common endocrine manifestation
of Carney complex (7) and can lead to ACTH-
independent Cushing’s syndrome (8). Testosterone
hypersecretion from PPNAD has also been described
in two female patients (9). In addition, the autonomous
cortisol production by the adrenal nodules reacts
paradoxically to dexamethasone administration in
69% of patients during the course of Liddle’s test (8),
due to increased glucocorticoid receptor (GR (NR3C1))DOI: 10.1530/EJE-12-0594
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between the GR and the PKA catalytic subunits (11).
Macronodular adrenal hyperplasia and adrenocorti-
cal adenomas with autonomous cortisol production
can be associated with aberrant expression of one of
several eutopic and ectopic G-protein-coupled receptors
(GPCRs) that are functionally coupled to steroidogenesis
(12, 13). Eutopic or ectopic GPCR expression does not
appear to play a major role in controlling steroidogen-
esis in PPNAD, unlike in macronodular hyperplasia
or solitary adrenocortical adenomas (14), although
clinical testing for aberrant responses has only been
reported for two PPNAD patients (10).
Here, we describe a patient presenting with viriliza-
tion and subclinical Cushing’s syndrome due to PPNAD
and a single adenoma that developed in her right
adrenal. We performed several in vivo stimulation tests
to screen for eutopic or ectopic stimuli that could
possibly regulate the peculiar hypersecretion of cortisol
and androgens. To obtain further insight in the
regulation of steroidogenesis in this single tumor,
in vitro studies were performed in which we examined
the effects of ACTH and dexamethasone on steroido-
genic enzyme expression and steroid production. In
addition, expression levels of the testosterone-producing
enzymes 17b-hydroxysteroid dehydrogenase (17b-HSD)
types 3 and 5 and of the glucocorticoid and androgen
receptors were measured in PPNAD as well as in
other adrenal tissues.Materials and methods
Clinical case
A 33-year-old Caucasian woman was referred to our
department because of primary infertility and hyper-
androgenism. The patient had been investigated for
infertility for several years. Two years before referral,
fertility screening showed no abnormalities in theTable 1 Serum hormone levels.
Reference
values
At
presentation
Aft
sy
Cortisol (nmol/l) 200–800 263
Testosterone (nmol/l) 0.5–3 9.7
17-OHP (nmol/l) 0.5–10 30
Androstenedione (nmol/l) 2–15 14
11-Deoxycortisol (nmol/l) 0–50 40
DHEA (nmol/l) 1.4–25 7.2
DHEAS (mmol/l) 0.8–10 1.00
Estradiol (pmol/l) 100–1000 256
ACTH (pmol/l) 0–11 !1.1
LH (U/l) 2–8 4.4
FSH (U/l) 1–8 9.2
Urine cortisol (nmol/day) 0–850 455
www.eje-online.orgpatient or her partner. Six intra-uterine insemination
sessions and an IVF attempt did not result in pregnancy.
The patient was then referred to the Department of
Gynecology of our center for a second opinion; here,
laboratory analysis showed an increased serum level
of testosterone.
The patient had menarche at the age of 13 years.
Soon thereafter, she started using oral contraceptives
because of facial acne and hirsutism. Seven years before
presentation, the patient stopped oral contraceptive use
and regained regular menstrual cycles. She noticed
increased and coarse hair on her face, abdomen, and
upper legs with concomitant frontotemporal hair loss.
During the past years, libido had increased and her
clitoris grew larger. Her past medical history and family
history were unremarkable nor did she take any
medication or hormonal preparations.
Upon physical examination, the patient displayed a
female phenotype with overt hirsutism and a male
pattern baldness. Her extremities and torso were
covered with multiple lentigines; clitoromegaly was
confirmed upon pelvic examination. Endocrinological
evaluation showed increased levels of testosterone and
17-hydroxyprogesterone (17-OHP) and a suppressed
ACTH level (Table 1). Morning and midnight cortisol
levels were 263 and 246 nmol/l respectively. Cortisol
and androgen levels were not adequately suppressed
after the overnight 1 mg dexamethasone test. Abdominal
CT scan subsequently showed a nodular enlargement
in the right adrenal (19!14 mm). Hounsfield units
measured 45 at basal, rising to 135 after i.v.
administration of contrast. Magnetic resonance
imaging (MRI) confirmed the right adrenal nodule
(Fig. 1A) with increased signal on the T2-weighted
image, which enhanced after i.v. gadolinium admini-
stration. No signal loss was observed during the
washout phase.
The patient was tested for ectopic hormone
receptor expression by measuring cortisol, 17-OHP,Preoperative Postoperative
er 250 mg
nacthen
1 mg Dexamethasone
overnight 1 week 27 months
419 298 226 337
10.1 7.5 !0.1 0.4
31 25.9 3.1 2.2
17.4 14.5 1.14 !1.05
48 21
12.5 4.1 5.3
1.01 !0.41 0.52
279
!1.1 11.7
1
1.4
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Figure 1 (A) Abdominal T1-weighted MRI revealed the presence
of a hyperintense lesion in the right adrenal. Photomicrographs
of the resected right adrenal: (B) large eosinophilic cells comprising
the large black node. Several areas with increased intracellular
pigmentation can be appreciated (magnification, 200!).
(C) Several smaller nodules were found dispersed in the remaining
adrenal cortex (magnification, 50!). (D) Immunohistochemical
staining for b-catenin showed membrane and cytoplasmic staining
of the adenoma (magnification, 800!).
Steroidogenesis in virilizing PPNAD 69EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168androstenedione, and testosterone at several time points
following LH-releasing hormone (100 mg i.v.), thyro-
tropin-releasing hormone (200 mg i.v.), glucagon (1 mg
i.v.), metoclopramide (10 mg i.v.), and arginine–vaso-
pressin (10 IU i.m.) administration; a standard mixed
meal (116 g carbohydrates, 27 g proteins, and 14 g fat);
and an upright posture test (15). The patient failed to
show an increase in steroid levels of O50% after
stimulation by the above-mentioned procedures.
The patient underwent an open right-sided adrena-
lectomy because of the suspicion of adrenocortical
cancer. Postoperative testing showed nondetectable
testosterone, DHEAS, and ACTH levels, whereas
17-OHP and androstenedione concentrations were
markedly diminished (Table 1). Pathological exami-
nation of the right adrenal showed a ‘black’, round
adenoma that measured w2 cm in diameter. Micro-
scopically, the tumor consisted of eosinophilic cells with
extensive granular pigmentation (Fig. 1B). The tumor
was embedded within an atrophic adrenal cortex
peppered with multiple other pigmented nodules
(Fig. 1C). The histopathological picture of the remaining
cortex was consistent with that of PPNAD (1).
Immunohistochemistry of b-catenin, using a mouse
MAB (#610154, diluted 1:200, BD Biosciences,
San Jose, CA, USA (16)), displayed a membranous and
cytoplasmic staining in both the adenoma and the
surrounding cortex (Fig. 1D).
Leukocyte DNA sequencing, performed as published
elsewhere (17), revealed a previously reported
PRKAR1A protein-truncating Q28X mutation (18),
confirming the diagnosis of PPNAD. Separate sequ-
encing of microdissected adenoma and PPNAD
tissues, using methods (19) and primers (5) previouslyreported, subsequently showed no mutations in exon 3
of CTNNB1.
Screening of the patient for pituitary tumors and for
cardiac myxoma was negative, whereas the patient did
suffer from several nonfunctional benign thyroid nodules
and fibro-adenomas in both breasts. No family members
showed signs of Carney complex-associated disease.
Six months after the operation, the patient reported to
be 7 weeks pregnant. At 39 weeks of pregnancy, she
successfully gave birth to a healthy boy. Endocrinological
evaluation 2 years after operation showed a normal
HPA axis and normal levels of androgens (Table 1).Control samples
Patient samples for in vitro examination were also
obtained from one normal adrenal cortex obtained
at radical nephrectomy due to renal cell carcinoma,
from two patients with adrenocortical hyperplasia
due to metastasized ACTH-producing neuroendocrine
tumors and from four patients with adrenocortical
carcinoma. Analysis of the normal and hyperplastic
adrenal samples were combined in the group designated
as ‘controls’.
Three other patients with histologically proven
PPNAD and clinical Cushing’s syndrome were identified
and adrenal samples were subsequently used for mRNA
analysis. These included a 33-year-old female
(PPNAD2), a 24-year female (PPNAD3), and a
24-year-old male (PPNAD4). PPNAD2 also showed no
significant increases in cortisol production following
in vivo testing for aberrantly expressed GPCRs. None
of the PPNAD patients underwent the full Liddle’s test,
but PPNAD3 and PPNAD4 subjects did undergo a 7 mg
i.v. dexamethasone test, which increased cortisol levels
by 19 and 13% respectively. Other samples for mRNA
analysis of the 17b-HSD types 3 (HSD17B3) and 5
(AKR1C3) and steroid receptors included normal
adrenals (nZ7), ACTH-dependent hyperplasia
(nZ10), and clinically nonfunctional (nZ3), cortisol-
(nZ6) and aldosterone-secreting (nZ6) adrenocortical
adenomas.
Informed consent was obtained from all patients
before operation. The study was approved by the
Medical Ethics Committee of the Erasmus MC and the
DNA studies were completed under an approved Eunice
Kennedy Shriver National Institute of Child Health and
Human Development clinical protocol.Tissue processing
Shortly after resection, adrenal tissue samples were
snap-frozen and kept at K80 8C for mRNA analysis or
put in DMEM-F12 (Invitrogen) containing 5% FCS,
penicillin, and streptomycin (Invitrogen) for purposes of
primary culture. A monolayer culture was obtained by
treating the tissue with collagenase (Sigma–Aldrich) as
described previously (20). After allowing the cells towww.eje-online.org
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free medium. The next day, cells were incubated with
vehicle, 10 ng/ml ACTH1–24 (Novartis) or 1 mM dexa-
methasone (Sigma–Aldrich). After 48 h of incubation,
the supernatants were removed and stored at K20 8C;
cells were simultaneously snap-frozen and stored at
K80 8C. Hormone measurements were performed as
previously reported (19).5000
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RNA was isolated from plated cells and homogenized
frozen adrenal tissues with TRIzol reagent (Invitrogen).
RNA measurement, reverse transcriptase reactions, and
quantitative PCR (qPCR) were performed as described
previously (21). The qPCR was performed in a 12.5 ml
volume for HPRT1, STAR, CYP11A1, HSD3B2,
CYP17A1, CYP21A2, CYP11B1 (21), AKR1C3,
HSD17B3, and steroid receptors GR and AR (assay
on demand, Hs00366267_m1, Hs00970002_m1,
Hs00230818_m1, and Hs00907242_m1, Applied
Biosystems). Expression levels were calculated relative
to that of the housekeeping gene HPRT1, expression
of which was stable between incubations and the
different groups of tissues, using the dCt method.
Immunohistochemistry of HSD17B3 and AKR1C3
protein was performed with methods equal to that
of b-catenin staining, using MABs purchased from
Sigma–Aldrich (HPA015307, 1:30) and Abcam
(ab49680, 1:3000) respectively.0
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Carcinoma (n = 4)Statistical analysis
All data on steroid hormone levels and mRNAs were
analyzed using paired t-test or one-way ANOVA with
post hoc Newman–Keuls multiple comparison test.
Logarithmic conversion was applied to obtain normality
if necessary. Statistical significance was assumed at
P!0.05.3
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Figure 2 (A) Cortisol, androstenedione (A’dione), and testosterone
levels in the supernatant of primary cultures following 48 h of ACTH
or dexamethasone incubation. mRNA levels of steroidogenic
enzymes in primary cultures of the PPNAD, normal and hyperplastic
adrenals (control, nZ3), and adrenocortical carcinomas (nZ4)
following 48 h of ACTH (B) or dexamethasone (C) incubation.
*P!0.05, **P!0.01, ***P!0.001 compared with control. Data are
expressed as meanGS.E.M.Results
Primary cultures
Primary cultures were obtained from the patient’s
adrenal tissue, one normal adrenal, two hyperplastic
adrenals, and four adrenocortical carcinomas. Forty-
eight-hour incubation with ACTH of the patients’ tumor
cells led to significant increases in cortisol (5.3-fold),
androstenedione (4.9-fold), and testosterone (3.6-fold)
levels (Fig. 2A). The increase in cortisol secretion
following ACTH stimulation in the control group was
6.8-fold and that of androstenedione 3.7-fold, whereas
ACTH did not stimulate testosterone production by
normal adrenal cells. Dexamethasone incubation did not
alter steroid levels compared with vehicle. All steroido-
genic enzymes studied were present in cells from thewww.eje-online.orgPPNAD. Of the predominant human 17b-HSD isoforms
that are known to be involved in testosterone pro-
duction, AKR1C3 mRNA expression in the cultured
PPNAD cells was 68-fold higher than that of HSD17B3Downloaded from Bioscientifica.com at 09/11/2019 07:12:10AM
via free access
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CYP17A1, CYP21A2, and CYP11B1 in the PPNAD
(Fig. 2B), whereas dexamethasone had no significant
effect on steroidogenic enzyme mRNAs (Fig. 2C). Also,
in control and carcinomatous adrenals, ACTH stimu-
lated steroidogenic enzyme expression whereas dexa-
methasone did not affect these mRNAs.100
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The mRNA levels of HSD17B3 and AKR1C3 were
measured in the fresh frozen tissue samples of the
patient’s tumor, three other PPNAD samples, normal
adrenals, and adrenocortical adenomas. Overall, adre-
nal AKR1C3 levels were higher than those of HSD17B3.
Within the PPNAD group, our patient had the highest
levels of AKR1C3 and HSD17B3 (Fig. 3, depicted as a
filled square). Compared with all other adrenal samples,
the virilizing PPNAD had the highest expression of
HSD17B3. Of the different adrenal tissues, nonfunc-
tional adenomas had higher levels of AKR1C3 mRNA
expression compared with cortisol-producing adenomas
(P!0.05, Fig. 3). Immunohistochemistry of both types
of 17b-HSD revealed specific, cytoplasmic staining in
the control adrenals. AKR1C3 was expressed in the
zona reticularis and clustered to a lesser extent in the
zona glomerulosa, whereas HSD17B3 was expressed in
the zona reticularis and adrenal medulla (Fig. 3). In the
PPNAD tissue, both proteins showed a heterogeneous
staining pattern among the large adenoma, the small
nodules, and the remaining cortex. Staining of AKR1C3
was more intense in the PPNAD-associated adenoma
than in the surrounding cortex or normal adrenals
and more prevalent than that of HSD17B3 (Fig. 3).
Because of the paradoxical rise in cortisol after
dexamethasone described in cases of PPNAD and the
hyperandrogenism of the current PPNAD case, we
also measured GR and AR mRNAs in these samples
in order to investigate potential feed-forward loops of
steroid receptor levels and glucocorticoid or androgen
overproduction. The steroid receptor mRNAs were
expressed in all samples, but there were no significant
differences between GR or AR expression in any of
the tissue types that were studied (Fig. 3).0.01
0.1
0.1
R
el
at
ive
Normal Hyp PPNAD NFA CPA Conn Normal Hyp PPNAD NFA CPA Conn
Figure 3 AKR1C3, HSD17B3 (top panels), GR, and AR (bottom
panels) mRNA expression in normal adrenal glands, adreno-
cortical hyperplasia (Hyp), PPNAD, and nonfunctional (NFA),
cortisol-producing (CPA), and aldosterone-producing (Conn)
adrenocortical adenomas. The virilizing PPNAD is depicted as
a filled square. Expression is calculated relative to that of the
housekeeping gene HPRT1. Bar denotes mean. *P!0.05. In the
centre: immunohistochemistry of AKR1C3 and HSD17B3 showed
a cytoplasmic but heterogeneous staining pattern in the PPNAD-
associated adenoma. The remaining cortex and smaller nodules
showed a similar pattern, with AKR1C3 as the predominant
17b-HSD (magnification, 50!).Discussion
As the first description of Carney complex in 1985 (1),
the genetic basis of the disease has been elucidated for
the majority of the patients (22). However, the factors
controlling the development of clinically significant
PPNAD in individual patients remain largely unknown.
A patient presenting with PPNAD with primary
infertility has not been described previously. The high
serum levels of androgens and androgen precursors,
combined with the absence of a cortisol diurnal rhythm
and a suppressed ACTH, led to the discovery of anadrenal tumor with atypical radiological features. As
such high androgen levels have not been previously
reported for PPNAD and the patient’s left adrenal
showed no abnormalities, an adrenocortical carcinoma
was suspected and an open adrenalectomy was
subsequently performed. Removal of the tumor led to
normalization of serum androgen levels and a successful
pregnancy within a few months. The steroid-secreting
PPNAD-associated adenoma was the cause of the
patient’s primary infertility, as the serum steroid profile
normalized after unilateral adrenalectomy despite the
remaining left adrenal presumably also being affected by
PPNAD. Unlike a previous report (23), this adenoma
was not associated with CTNNB1 mutations or
constitutive b-catenin activation. This could reflect
that only a subset of PPNAD-associated adenomas iswww.eje-online.org
Downloaded from Bioscientifica.com at 09/11/2019 07:12:10AM
via free access
72 J Hofland and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168characterized by these mutations, as is the case in
sporadic adrenocortical adenomas (24, 25).
Steroid overproduction in PPNAD usually results in a
mild, ACTH-independent form of Cushing’s syndrome
(8). As is evident from our case, other steroids can also
be produced in PPNAD, leading to a very different
clinical presentation. The Q28X mutation (18) has been
detected in two previous patients. These female relatives
displayed lentigines, breast myxomas, and PPNAD, but
without hyperandrogenism. Recent studies in adrenal
cortex-specific Prkar1a knockout mice showed that PKA
R1a loss is sufficient to drive PPNAD development and
autonomous steroidogenesis. ACTH responsiveness
remained intact in these mice (26). Human adrenal
cells with mutated PRKAR1A remain cAMP responsive
and increase PKA activity even more compared with
nonmutated cells as PRKAR1A mutations lead to
constitutive PKA activity (2, 9). In vivo and in vitro
studies of our patient showed that the PPNAD cells still
possessed the ability to respond to ACTH; production of
cortisol, androstenedione, and testosterone increased
after exposure to ACTH. The ACTH responsiveness in
terms of cortisol and androstenedione was comparable
between normal adrenocortical and the patient’s
PPNAD cells. However, results for testosterone differed:
in the control cells, no increase of testosterone
production was detected, whereas testosterone pro-
duction by the PPNAD cells was significantly stimulated
by ACTH. The ACTH effect as measured by steroidogenic
enzyme mRNA expression levels showed an augmented
and diminished response for CYP11B1 and HSD3B2
respectively making it possible that there was an
aberrant regulation of steroidogenesis in the patient’s
PPNAD cells.
Testosterone is mainly formed from androstenedione
by 17b-HSD types 3 and 5, encoded by HSD17B3 and
AKR1C3 respectively (27). Whereas HSD17B3 is the
predominant testosterone-forming enzyme in the testis,
AKR1C3 mainly ensures testosterone formation in
nontesticular tissues, such as the adrenal cortex (28)
and prostate gland (29). Our patient showed particu-
larly high mRNA levels of HSD17B3 compared with all
other adrenal tissues, but this could not be confirmed by
immunohistochemistry. AKR1C3 mRNA expression in
this PPNAD was augmented compared with the other
PPNAD samples and staining of the enzyme revealed
positive cell clusters in the large adenoma. Given the
higher levels compared with HSD17B3, AKR1C3 forms
the principal candidate for the cause of hyperandrogen-
ism in our patient, presumably due to mass effect in the
dominant nodule. The origin of the augmented
17b-HSD type 5 levels in this PPNAD-associated
adenoma remains elusive as the factors that control
adrenocortical AKR1C3 expression are unknown.
In vivo studies in our original patient and PPNAD2 did
not show evidence for ectopic expression of hormone
receptors known to aberrantly control adrenal function
in macronodular hyperplasia. This finding is consistentwww.eje-online.orgwith the two other cases described previously (10).
It therefore appears unlikely that aberrant GPCR-
signaling stimuli regulate increased adrenocortical
steroidogenesis in human PPNAD cells.
The paradoxical rise in serum cortisol levels following
Liddle’s test implied that glucocorticoids can locally
regulate adrenocortical steroidogenesis in the majority
of PPNAD. Dexamethasone incubation in primary cells
from our patient’s PPNAD did not stimulate steroid
secretion or steroidogenic enzyme mRNA levels, com-
parable to the effects in normal and malignant adrenal
cells. This implies that overproduction of cortisol and
androgens was present without stimulatory effects of
the GR. Although the constitutively activated cAMP–
PKA pathway could be sufficient cause for the hormonal
syndrome in the patient, it could also be speculated
that mechanisms different from glucocorticoid
action are involved in steroidogenic control within
PPNAD-associated adenomas. In addition, using qPCR,
we could not show an increased expression of GRmRNA
in PPNAD samples from four patients, two of whom
showed slightly augmented cortisol levels after dexa-
methasone in vivo. This finding suggests that in at least
some PPNAD tissues, aberrant coupling of the GR to the
cAMP–PKA pathway (11) instead of GR overexpression
(10) may be the culprit for the dexamethasone-induced
rise in cortisol production. Other steroid receptors, such
as the progesterone and estrogen receptors, have also
been detected in PPNAD tissue (30). The finding that
AR mRNA is present in PPNAD is novel, although the
AR appears to be expressed similarly in the various
adrenal tissues that were examined in this study.
In conclusion, we described a novel clinical presen-
tation for PPNAD, a female with primary infertility due
to a virilizing adenoma formed in the context of PPNAD.
Successful pregnancy ensued upon adrenalectomy. This
tumor also had a unique steroid secretion profile in vitro,
suggesting that defects of the PKA pathway may also
affect secretion of additional steroids, apart from
glucocorticoids. The steroidogenic regulation in this
PPNAD-associated adenoma may be different from that
in PPNAD without adenomas.Declaration of interest
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